Search Videos by Topic or Participant
Browse by Series:

Emerging Concepts in Multiple Myeloma

Panelists:
Published: Thursday, Oct 29, 2015

 
There are still unmet needs in multiple myeloma, states Morie A. Gertz, MD. Advancements in the understanding of appropriate combinations and the development of new drug classes are imperative for the myeloma community, Gertz notes. Learning the biology and genetics of the disease and clonal heterogeneity of each individual patient is also essential, adds Heather J. Landau, MD.

Sequencing therapies and optimal utilization of existing therapies are other areas of advancement on the horizon, comments Jatin J. Shah, MD. The treatment of myeloma is different than other malignancies, since patients can be retreated with therapies. There is not going to be one standard of care, notes Shah.

Incremental progress is still progress, and it improves the lives of patients with multiple myeloma, says Rafael Fonseca, MD. For example, the toxicity profiles of the immunomodulatory drugs (IMiDs) have improved since thalidomide was introduced; next-generation IMiDs, lenalidomide and pomalidomide, are better tolerated, explains Fonseca.
 
Slider Left
Slider Right

 
There are still unmet needs in multiple myeloma, states Morie A. Gertz, MD. Advancements in the understanding of appropriate combinations and the development of new drug classes are imperative for the myeloma community, Gertz notes. Learning the biology and genetics of the disease and clonal heterogeneity of each individual patient is also essential, adds Heather J. Landau, MD.

Sequencing therapies and optimal utilization of existing therapies are other areas of advancement on the horizon, comments Jatin J. Shah, MD. The treatment of myeloma is different than other malignancies, since patients can be retreated with therapies. There is not going to be one standard of care, notes Shah.

Incremental progress is still progress, and it improves the lives of patients with multiple myeloma, says Rafael Fonseca, MD. For example, the toxicity profiles of the immunomodulatory drugs (IMiDs) have improved since thalidomide was introduced; next-generation IMiDs, lenalidomide and pomalidomide, are better tolerated, explains Fonseca.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x